Stryker Corporation $SYK Stock Position Boosted by Heartland Bank & Trust Co

Heartland Bank & Trust Co raised its stake in shares of Stryker Corporation (NYSE:SYK) by 98.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,489 shares of the medical technology company’s stock after buying an additional 2,224 shares during the period. Heartland Bank & Trust Co’s holdings in Stryker were worth $1,475,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of Stryker by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company’s stock valued at $11,917,396,000 after acquiring an additional 133,892 shares during the period. State Street Corp raised its holdings in Stryker by 2.1% during the fourth quarter. State Street Corp now owns 15,254,407 shares of the medical technology company’s stock worth $5,374,731,000 after purchasing an additional 311,507 shares in the last quarter. Geode Capital Management LLC lifted its position in Stryker by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company’s stock worth $2,636,238,000 after purchasing an additional 69,851 shares during the period. Wellington Management Group LLP boosted its stake in Stryker by 22.6% during the 4th quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock valued at $2,282,192,000 after purchasing an additional 1,198,665 shares in the last quarter. Finally, Norges Bank bought a new position in Stryker during the 4th quarter valued at $1,822,272,000. 77.09% of the stock is currently owned by institutional investors.

Key Stories Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker launched Mako RPS, a new handheld robotic power system for total knee replacement, expanding its Mako robotics portfolio beyond robotic-arm assisted surgery and potentially broadening adoption of robotic-assisted orthopedic procedures. Stryker expands Mako robotics portfolio with full market release of Mako RPS
• Positive Sentiment: Media coverage highlighted the full U.S. commercial launch of Mako RPS, reinforcing investor optimism that Stryker is strengthening its competitive position in orthopedic robotics. Stryker fully launches Mako robotic power system for knee surgery in US
• Positive Sentiment: Unusually heavy call-option buying suggested traders were positioning for more upside in SYK, which can sometimes add momentum to the shares.
• Positive Sentiment: RBC Capital reiterated its Buy rating on Stryker, providing another favorable signal from the analyst community. RBC Capital Sticks to Their Buy Rating for Stryker (SYK)
• Neutral Sentiment: MarketWatch noted that Stryker stock outperformed peers on a strong trading day, indicating relative strength but without a specific new company catalyst. Stryker Corp. stock outperforms competitors on strong trading day
• Neutral Sentiment: Analyst commentary on Stryker was mixed in broader healthcare-sector coverage, but no major negative surprise was indicated in the headlines provided. Analysts Offer Insights on Healthcare Companies: Shionogi & Co (OtherSGIOF) and Stryker (SYK)

Stryker Price Performance

Shares of NYSE:SYK opened at $319.78 on Friday. Stryker Corporation has a one year low of $281.00 and a one year high of $404.87. The stock has a fifty day moving average of $312.69 and a 200-day moving average of $336.82. The company has a market capitalization of $122.59 billion, a PE ratio of 37.01, a price-to-earnings-growth ratio of 2.12 and a beta of 0.77. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The company had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The business’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities analysts anticipate that Stryker Corporation will post 14.99 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s dividend payout ratio (DPR) is currently 40.74%.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 310,000 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the transaction, the director directly owned 1,924,880 shares in the company, valued at $601,005,282.40. This trade represents a 13.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, VP M Kathryn Fink sold 3,500 shares of Stryker stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $283.45, for a total transaction of $992,075.00. Following the completion of the transaction, the vice president directly owned 177 shares in the company, valued at approximately $50,170.65. This trade represents a 95.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 323,264 shares of company stock worth $100,659,489. Company insiders own 4.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on SYK shares. Weiss Ratings downgraded Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 4th. JPMorgan Chase & Co. decreased their target price on Stryker from $445.00 to $400.00 and set an “overweight” rating for the company in a research note on Friday, May 1st. Wall Street Zen lowered Stryker from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Truist Financial reiterated a “hold” rating and issued a $330.00 price target (down from $380.00) on shares of Stryker in a research report on Monday, May 4th. Finally, BMO Capital Markets assumed coverage on shares of Stryker in a report on Wednesday, July 8th. They issued an “outperform” rating and a $369.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $392.52.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.